First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution

Simple item page
dc.contributor.authorWalbaum, Benjamin
dc.contributor.authorAcevedo, Francisco
dc.contributor.authorMedina, Lidia
dc.contributor.authorBravo, M. Loreto
dc.contributor.authorMerino, Tomas
dc.contributor.authorCamus, Mauricio
dc.contributor.authorDominguez, Francisco
dc.contributor.authorMondaca, Sebastian
dc.contributor.authorGalindo, Hector
dc.contributor.authorNervi, Bruno
dc.contributor.authorIbanez, Carolina
dc.contributor.authorMadrid, Jorge
dc.contributor.authorPena, Jose
dc.contributor.authorKoch, Erica
dc.contributor.authorGarrido, Marcelo
dc.contributor.authorPinto, Mauricio P.
dc.contributor.authorSanchez, Cesar
dc.date.accessioned2024-01-10T13:48:25Z
dc.date.available2024-01-10T13:48:25Z
dc.date.issued2020
dc.description.abstractObjective: Clinical guidelines recommend the use of endocrine therapy (ET) in advanced hormone receptor positive (HR+) human epidermal growth factor receptor type 2 negative (HER2-) breast cancer (BC) patients in the absence of visceral disease or ET resistance. Furthermore, studies indicate similar response and survival rates using ET or cytotoxic chemotherapy (CT). Methods: Herein, we assessed clinical characteristics, type of systemic therapy and survival rates of advanced HR + HER2-BC patients in our database. Results: A total of 172 advanced HR + HER2-BC patients were treated at our institution between 1997 and 2019. Sixty percent received first-line ET (4% received combined ET). Median age of this subset was 55 years (range: 30-86). Similarly, the median age of patients that received CT was 54 years (range: 21-83). Over time, 30% of patients received ET in the 2000-2005 period; this increased to 70% in the 2016-2019 period (p = .045). Overall survival (OS) was 97 months and 51 months for patients treated with ET or CT, respectively (p = .002). Conclusions: To the best of our knowledge this is the first study assessing the use of ET in Chilean advanced HR + HER2-BC patients. Several patients in our institution receive CT without indication. The increase in ET usage over time can be attributed to better and faster immunohistochemical detection methods for Estrogen Receptor (ER), changes in educational and government policies, and a wider variety of ET options. Finally, clinical trials have failed to demonstrate a substantial benefit of CT over ET in this setting.
dc.fechaingreso.objetodigital2024-05-08
dc.format.extent5 páginas
dc.fuente.origenWOS
dc.identifier.doi10.1080/03007995.2020.1763282
dc.identifier.eissn1473-4877
dc.identifier.issn0300-7995
dc.identifier.pubmedidMEDLINE:32351137
dc.identifier.urihttps://doi.org/10.1080/03007995.2020.1763282
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/79364
dc.identifier.wosidWOS:000534141800001
dc.information.autorucMedicina;Cesar Sanchez;S/I;119017
dc.issue.numero7
dc.language.isoen
dc.nota.accesocontenido parcial
dc.pagina.final1199
dc.pagina.inicio1195
dc.publisherTAYLOR & FRANCIS LTD
dc.revistaCURRENT MEDICAL RESEARCH AND OPINION
dc.rightsacceso restringido
dc.subjectHormonal antineoplastics
dc.subjectbreast neoplasm
dc.subjectendocrine breast disease
dc.subjectchemotherapy
dc.subjectPATTERNS
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleFirst-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution
dc.typeartículo
dc.volumen36
sipa.codpersvinculados119017
sipa.indexWOS
sipa.indexPubmed
sipa.trazabilidadCarga SIPA;09-01-2024
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024-05-08. First-line endocrine therapy for advanced breast cancer. A real-world study at a Latin American university health institution.pdf
Size:
3.21 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas